(Z)-Endoxifen as a Potential Modulator of Utrophin Pathways in Duchenne Muscular Dystrophy: A Mechanistic and Transcriptomic Perspective
Open Access
- 1 May 2026
- journal article
- review article
- Published by Taylor & Francis in Degenerative Neurological and Neuromuscular Disease
- Vol. ume 16, 1-16
Abstract
Duchenne muscular dystrophy (DMD) is a fatal X-linked neuromuscular disorder caused by mutations in the dystrophin gene, leading to sarcolemmal instability, chronic calcium overload, mitochondrial dysfunction, inflammation, and fibrosis. These effects manifest clinically as muscle atrophy, loss of mobility, and respiratory and cardiac insufficiencies. Although gene-targeted approaches such as exon skipping and microdystrophin delivery have advanced, their applicability is restricted by genotype and adverse effects. Thus, reasonably safe, effective therapies remain a critical unmet need. (Z)-endoxifen, the (Z)-isomer of endoxifen, is the principal active metabolite of tamoxifen, exhibiting higher potency in protein kinase C (PKC) inhibition than tamoxifen and regulating various protein activities differently than tamoxifen. This pharmacologic profile positions endoxifen to address multiple DMD pathological mechanisms simultaneously. Recent literature supports the prior hypothesis that endoxifen exerts pleiotropic benefits in DMD. Transcriptomic and preclinical evidence shows that endoxifen may have superior effects to tamoxifen in reversing DMD signatures given available dosing regimens. Additionally, pathway-level insights support endoxifen activation of myogenesis, oxidative phosphorylation, estrogen receptor beta (ERβ) activation, and inhibition of pro-inflammatory and epithelial-to-mesenchymal transition (EMT) pathways in DMD. These findings suggest (Z)-endoxifen may act on utrophin-linked regulatory axes, thereby potentially contributing to functional compensation for dystrophin deficiency. This provides justification for endoxifen’s development as a mutation-agnostic DMD therapeutic approach.Keywords
This publication has 91 references indexed in Scilit:
- Cardiac atrial pathology in Duchenne muscular dystrophyMuscle & Nerve, 2024
- Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative ReviewBioDrugs, 2023
- Evolving Therapeutic Options for the Treatment of Duchenne Muscular DystrophyNeurotherapeutics, 2023
- Proteomic profiling of impaired excitation–contraction coupling and abnormal calcium handling in muscular dystrophyProteomics, 2022
- Systemic cell therapy for muscular dystrophiesStem Cell Reviews and Reports, 2020
- Alternative utrophin mRNAs contribute to phenotypic differences between dystrophin‐deficient mice and Duchenne muscular dystrophyFEBS Letters, 2018
- Corticosteroids for the treatment of Duchenne muscular dystrophyCochrane Database of Systematic Reviews, 2016
- The Dystrophin Complex: Structure, Function, and Implications for Therapy2015
- The Anticancer Drug Tamoxifen Counteracts the Pathology in a Mouse Model of Duchenne Muscular DystrophyThe American Journal of Pathology, 2013
- Dystrophin: The protein product of the duchenne muscular dystrophy locusCell, 1987